Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
SVNT: Stock Quote & Summary Data
1.36%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | $ 18.00 |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 2,138,917 |
| Previous Close | $ 14 |
| 52 Wk High / Low | $ 16.62 / $ 2.9798 |
| Shares Outstanding | 66,567,000 |
| Market Value | $ 919,290,270 |
| P/E Ratio | NE |
| Forward P/E (1yr) | NE |
| Earnings Per Share | $ -2.01 |
| Annualized Dividend | N/A |
| Ex Dividend Date | N/A |
| Dividend Payment Date | N/A |
| Current Yield | N/A |
| Beta | 1.11 |
| NASDAQ Official Open Price: | $ 13.92 |
| Date of NASDAQ Official Open Price: | Nov. 20, 2009 |
| NASDAQ Official Close Price: | $ 13.81 |
| Date of NASDAQ Official Close Price: | Nov. 20, 2009 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About SVNT?
Ask your question about about Savient Pharmaceuticals Inc (SVNT) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
We are a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader markets. We are currently developing Puricase®, which we refer to as pegloticase, which is being developed for the control of uric acid in patients with gout whose signs and symptoms are inadequately controlled by conventional urate lowering therapy due to ineffectiveness, dose limiting toxicity, hypersensitivity or other contraindications. In 2001, pegloticase received “orphan drug” designation by the U.S. Food and Drug Administration, or FDA, which may allow it to receive orphan drug exclusivity if and when pegloticase is approved. Orphan drug exclusivity may prevent competitive versions of the same drug for the same indication from entering the market for a period of seven years from the time of FDA approval of pegloticase. ... More ...
Links to all Savient Pharmaceuticals Inc (SVNT) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for SVNT |
||
|
Savient Pharmaceuticals Q3 09 Earnings Conference Call At 10:00 AM - RTT News 11/05/2009 9:04AM |
||
|
Savient Pharma Q3 Loss Narrows - Quick Facts - RTT News 11/04/2009 7:42PM |
||
|
Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results - PR Newswire 11/04/2009 7:23PM |
||
|
RothmanResearch.com Market Review and Company Analysis on SYNA, ARUN, CELG, SVNT, PRGN and SWHC - Market Wire 11/04/2009 5:30AM |
||
|
Savient Pharmaceuticals To Present At The Oppenheimer 20th Annual Healthcare Conference; Webcast At 1:35 PM - RTT News 11/03/2009 12:44PM |
||
|
Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009 - PR Newswire 10/28/2009 6:32PM |
||
|
Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference - GlobeNewswire 10/27/2009 4:30PM |
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $ -1.84 |
| Quarterly EPS Est: | $ -0.29 |
| PEG Ratio: | N/A |
| Mean Recommendation: View Summary/View All |
2.11 |
